Nephrogenex: Rodman & Renshaw Global Investment Conference (Nephrogenex) - Sep 11, 2014 - Anticipated method of use (patient population and dosage) patent expiry in US in Dec 2028; Anticipated manufacturing patent expiry in US in Feb 2025; Anticipated patent term extension in EU until Jun 2029
Anticipated patent expiry • Renal Disease
|